ArticleFrontiers in endocrinology2026
Anti-Müllerian hormone in relation to adiposity and metabolic indices in polyendocrine metabolic ovarian syndrome.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-Müllerian hormone (AMH) is widely used as a marker of ovarian reserve and is also incorporated into the diagnostic assessment of polyendocrine metabolic ovarian syndrome (PMOS). Although PMOS is strongly associated with metabolic dysfunction and abnormal adipose tissue distribution, the relationship between AMH concentrations and adiposity, and especially visceral adiposity remains unclear. This study aimed to evaluate the association between serum AMH levels and selected adiposity and metabolic markers in women with PMOS. Methods: This cross-sectional study included 1147 women with newly diagnosed PMOS. Serum AMH, sex hormone-binding globulin (SHBG), glucose, insulin, lipid profile, and other hormonal parameters were assessed. Anthropometric measurements included body mass index (BMI), waist and hip circumference, and waist-to-hip ratio (WHR). Percent body fat (PBF) and visceral fat area (VFA) were assessed using bioelectrical impedance analysis. The lipid accumulation product (LAP), cardiometabolic index (CMI), and homeostatic model assessment of insulin resistance (HOMA-IR) were calculated. Results: AMH concentrations showed very weak inverse correlations with adiposity markers, WHR ( Conclusions: In women with PMOS, serum AMH concentrations are negligibly associated with adiposity markers despite strong relationships between these markers and metabolic dysfunction. Therefore, AMH levels should be interpreted primarily in the context of age and reproductive characteristics rather than as a direct marker of visceral adiposity or metabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.